December 31, | ||||||
2017 | 2016 | |||||
$ | $ | |||||
Onerous contract provisions (detailed below) | 310 | 404 | ||||
Non-current portion of provision for restructuring costs (note 13) | 718 | — | ||||
Other | — | 97 | ||||
1,028 | 501 |
Cetrotide® onerous contracts* | Onerous lease** | Total | |||||||
$ | $ | $ | |||||||
At January 1, 2016 | 803 | 234 | 1,037 | ||||||
Change in the provision | (24 | ) | — | (24 | ) | ||||
Utilization of provision | (196 | ) | (113 | ) | (309 | ) | |||
Unwinding of discount and effect of changes in the discount and foreign exchange rates | (9 | ) | 4 | (5 | ) | ||||
At December 31, 2016 | 574 | 125 | 699 | ||||||
Less: current portion (note 12) | (181 | ) | (114 | ) | (295 | ) | |||
393 | 11 | 404 | |||||||
At December 31, 2016 | 574 | 125 | 699 | ||||||
Change in the provision | (20 | ) | — | (20 | ) | ||||
Utilization of provision | (145 | ) | (119 | ) | (264 | ) | |||
Unwinding of discount and effect of changes in the discount and foreign exchange rates | 64 | 3 | 67 | ||||||
At December 31, 2017 | 473 | 9 | 482 | ||||||
Less: current portion (note 12) | (163 | ) | (9 | ) | (172 | ) | |||
310 | — | 310 |
* | Recorded following the transfer of the Cetrotide® Business (discontinued operations). |
** | Represents the present value of the future lease payments that the Company is obligated to make pursuant to a non-cancellable operating lease in the United States, net of estimated future sublease income. The estimate may vary as a result of changes in the utilization of the leased premises and of the sublease arrangement. The lease expired in January 2018. |